SCHEMBL5357917

SCHEMBL5357917

CN(C)C=Nc1ncc(C(=O)O)s1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.70
RAB9A P51151 5/20 0.70
SMN1; SMN2 Q16637 4/20 0.70
NPC1 O15118 3/20 0.70
KDM4E B2RXH2 5/20 0.64
MAPT P10636 4/20 0.64
MEN1 O00255 3/20 0.64
KMT2A Q03164 3/20 0.64
CYP1A2 P05177 3/20 0.61
CYP2C19 P33261 3/20 0.61
CYP3A4 P08684 1/20 0.61
CYP2D6 P10635 1/20 0.61
HPGD P15428 3/20 0.60
RECQL P46063 1/20 0.57
RXFP1 Q9HBX9 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
HCAR2 Q8TDS4 1/20 0.47
HTT P42858 1/20 0.35
NCOA1 Q15788 1/20 0.35
NCOA3 Q9Y6Q9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5357915 1.00 ALDH1A1 (0.70) ALDH1A1RAB9ASMN1; SMN2NPC1KDM4E
SCHEMBL23162497 0.87 ALDH1A1 (0.66) ALDH1A1RAB9ASMN1; SMN2NPC1KDM4E
SCHEMBL23162498 0.87 ALDH1A1 (0.66) ALDH1A1RAB9ASMN1; SMN2NPC1KDM4E
SCHEMBL23207060 0.87 ALDH1A1 (0.66) ALDH1A1RAB9ASMN1; SMN2NPC1KDM4E
SCHEMBL3112087 0.86 ALDH1A1 (0.73) ALDH1A1RAB9ASMN1; SMN2NPC1KDM4E
SCHEMBL3112082 0.86 ALDH1A1 (0.73) ALDH1A1RAB9ASMN1; SMN2NPC1KDM4E
SCHEMBL10110055 0.83 ALDH1A1 (1.00) ALDH1A1RAB9ASMN1; SMN2NPC1KDM4E
SCHEMBL3017850 0.82 ALDH1A1 (0.64) ALDH1A1RAB9ASMN1; SMN2NPC1KDM4E
SCHEMBL3017848 0.82 ALDH1A1 (0.64) ALDH1A1RAB9ASMN1; SMN2NPC1KDM4E
SCHEMBL5353564 0.80 ALDH1A1 (1.00) ALDH1A1RAB9ASMN1; SMN2NPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265134-B2 Tyrosine kinase inhibitors MERCK & CO., INC. (US) 2007-09-04 US disclosed
US-20040192926-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME CORP. 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192926-A1 Tyrosine kinase inhibitors ERBB2, TYRO3, TIE1 ALDH1A1 3104/4885RAB9A 2382/4885SMN1; SMN2 4473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.